Clinical Research Directory

2.5.1 Inclusion criteria * Age 18 years or above * Eastern Cooperative Oncology Group (ECOG) performance score 0-2 * Have known or suspected metastatic NSCLC at time of enrollment (including patients who progress on initial therapy or are found to have metastatic disease during therapy and are not excluded * Patient is able and willing to provide informed consent. * Rapid on-site cytopathologic examination (ROSE) performed during the procedure (if not previously diagnosed) and returns likely NSCLC. No injection will be performed if ROSE is non-diagnostic. * A CT scan of the chest (with or without contrast) within the prior 3 months. * The presence of an EBUS accessible target site determined by a treating investigator. These may be primary lung cancers or metastatic sites (including when a lymph node station has been replaced by metastatic tumor), that are accessible by EBUS. * MDC agreement of likely Stage IV NSCLC (confirmation from at minimum a Medical Oncologist and Radiation Oncologist on clinical stage). * Patients must have adequate organ and marrow function as defined below: * Leukocytes ≥3,000/mcL * Platelets ≥100,000/mcL * Total bilirubin ≤ institutional upper limit of normal (ULN) * AST(SGOT)/ALT(SGPT) ≤ institutional ULN * Creatinine ≤ institutional ULN 2.5.2 Exclusion criteria * Use of an investigational agent in prior 30 days * Pregnancy/lactation (pregnancy test to be performed by pre-op as part of standard of care for women of child-bearing age as defined by UVMMC Policy NPREP16) * Treatment with intravenous cytotoxic chemotherapy within the past 14 days * Allergy to cisplatin or its derivatives * Allergy to iodinated contrast * Patient not appropriate for the research study based on physician discretion